Home > Healthcare > Medical Devices > Diagnostic Devices > Premature Rupture of Membranes (PROM) Testing Market

Premature Rupture of Membranes (PROM) Testing Market Share

Report ID: GMI5895
Published Date: May 2023
Report Format: PDF

Download Free Sample

Premature Rupture of Membranes (PROM) Testing Market Share

Some of the notable key industry players operating in the premature rupture of membranes testing market include

Abbott Laboratories
QIAGEN
Hologic Inc.
Medix Biochemica
Biosynex
Clinical Innovations LLC
Sera Prognostics Inc.
The Cooper Companies Inc.
NX Prenatal Inc.
IQ Products

These market participants are undertaking numerous growth strategies such as partnerships, collaborations, acquisitions & mergers, and new product development & launches to strengthen product offerings as well as gain a competitive edge over others.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

Premature Rupture of Membranes Testing Market was valued at over USD 3 billion in 2022 and is projected to reach more than USD 5 billion by 2032 attributed to the increasing awareness about PROM-related complications and advancements in diagnostic technologies.

The nitrazine test segment is estimated to grow at 5.7% CAGR over 2023-2032 owing to ongoing technological advancements and integration of digital solutions in nitrazine tests to enhance accuracy, ease of use, and interpretation.

The U.S. premature rupture of membranes (PROM) testing market amassed USD 1 billion in 2022 and is anticipated to grow at a robust CAGR through 2032 driven by the high prevalence of preterm births across the nation.

Abbott Laboratories, QIAGEN, Hologic Inc., Medix Biochemica, Biosynex, Clinical Innovations LLC, Sera Prognostics Inc., The Cooper Companies Inc., NX Prenatal Inc., and IQ Products are some of the leading firms in the global premature rupture of membranes (PROM) testing industry.